



## Tuberculosis Vaccines and Novel Drug Development

Guest Editors:

**Dr. Sangeeta Tiwari**

Department of Biological  
Sciences, University of Texas at El  
Paso, El Paso, TX 79968, USA

**Dr. Shivani Singh**

Division of Pulmonary and  
Critical Care Medicine, New York  
University Grossman School of  
Medicine, NYU Langone Health,  
New York, NY, USA

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

Dear Colleagues,

Tuberculosis (TB) continues to be a major global health burden and kills over a million people annually. The emergence of drug-resistant strains has further worsened the situation that demands urgent need for vaccines and novel drug development against *Mycobacterium tuberculosis* (Mtb). The attenuated *Mycobacterium bovis* strain Bacille Calmette–Guerin (BCG) is the only FDA-licensed TB vaccine. BCG protects infants against disseminated TB, but it shows variable protection against adult pulmonary TB. Moreover, BCG can disseminate under immunosuppressed or immunocompromised conditions; hence, a safer and more efficacious TB vaccine is paramount. This requires a better understanding of the mechanisms that Mtb deploys to evade the host immune response.

This Special Issue welcomes all types of manuscripts providing insight into aspects relevant to TB vaccines and novel drug development. We are interested in a wide scope of work including but not limited to basic science research and clinical studies. We welcome the submission of original articles, reviews and other research articles that will improve our knowledge in these areas.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)